Products
AlbuRel™ is human normal albumin. Albumin is the most abundant protein in human plasma and is synthesized by the liver. Albumin is an effective plasma volume expander. AlbuRel™ is made virus safe by double pasteurization.
Among its multiple physiological roles, it plays an essential part in generation of colloid oncotic pressure. It is used for restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.
Albumin therapy is indicated in hypovolemia or shock, burns therapy, hypoalbuminemia, prevention of central volume depletion after paracentesis, acute respiratory distress syndrome (ARDS), acute nephrosis, renal dialysis, acute liver failure, cardiopulmonary bypass operation, hemolytic disease of the newborn and ovarian hyperstimulation syndrome.
AlbuRel™ is available in 20% concentration in 50 ml and 100 ml pack sizes, Alburel™-T (N-acetyl-DL-tryptophan as stabilizer) is available as 20% concentration in 100 ml and AlbuRel™ – OS (Optimum Sodium) is available as 20% concentration in 100 ml.
HemoRel-A is a 250 IU and 500 IU preparation of clotting factor VIII. HemoRel-A is indicated for replacement of factor VIII in patients, who have factor VIII deficiency i.e. patients diagnosed with haemophilia A. Factor VIII replacement is the therapy of choice for clotting disorder in haemophilia A.
HemoRel-A is purified Factor VIII manufactured by ion exchange chromatography. It contains intact Factor VIII complex i.e. F VIII:C and von Willebrand Factor (vWF) and fibrinogen is below detection levels. HemoRel-A is made virus safe by Double Viral Inactivation: by Solvent-Detergent method and Heat treatment.
The product pack is user-friendly and kit includes one 20 ml syringe, two needles, water for injection, syringe filter and spirit swab.
HepaRel™ is (Hepatitis B immunoglobulin – HBIG) prepared from human plasma collected from donors with high titre of antibodies to the hepatitis B surface antigen (anti HBsAg).
HepaRel™ (Hepatitis B immunoglobulin) is a solvent detergent treated and chromatographically purified sterile solution containing 10 – 50g/l protein and contains ≥ 90% Human immunoglobulin G. It has potency of 100 IU/ml or 200 IU/ml of hepatitis B antibodies to the hepatitis B surface antigen (HBsAg) as the active ingredient. It contains no preservative and is intended for administration by intra-muscular route for single dose. Available in 100 IU and 200 IU pack sizes.
HepaRel™ is indicated for post-exposure prophylaxis in the following situations, in prevention of hepatitis B in case of accidental exposure and prevention of hepatitis B in the newborn.
HepaRel™ (Hepatitis B immunoglobulin) provides passive immunization for individuals who are exposed to hepatitis B virus from different sources. HepaRel (Hepatitis B immunoglobulin) administration decreases the infection rate.
ImmunoRel® is a solvent detergent treated, chromatographically purified immunoglobulin G(IgG) derived from pooled human plasma.
The approved indications include Primary Immunodeficiency (PID), Kawasaki disease, Idiopathic Thrombocytopenic Purpura, B-cell Chronic lymphocytic leukaemia, Paediatric HIV 1 infection and Hemopoietic stem cell transplantation in elderly.
The clinical experience has also shown efficacy in GB syndrome, Multifocal Motor Neuropathy, CIDP, Lambert Eaton Myasthenic syndrome, Myasthenia Gravis, Neonatal Sepsis, Polymyositis, Dermatomyositis and few others.
The normal immunoglobulin is meant for intravenous use. ImmunoRel® is available in 5% concentrations in 10 ml, 20 ml, 50 ml and 100 ml pack sizes.
ReliSeal® is biological glue and haemostatic agent, which can be used in a variety of surgical procedures to arrest bleeding, seal tissues and as an adjunct to wound healing.
A quick acting surgical fibrin sealant derived from human blood plasma, with haemostatic sealing and adhesive properties, ReliSeal® mimics the final stage of the natural clotting mechanism.
The kit is available in 0.5 ml and 1 ml pack size.
FibrinoRel™ (Dried Fibrinogen) is a sterile, heat-treated, lyophilized fibrinogen (coagulation factor I) concentrate powder manufactured from pooled human plasma. Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa.
FibrinoRel™ (Dried Fibrinogen) is available as 1gram dried lyophilized powder solution for intravenous injection.
FibrinoRel™ (Dried Fibrinogen) is indicated for therapy and prophylaxis of haemorrhagic diatheses in congenital hypo-, dys- or afibrinogenemia and acquired hyperfibrinogenaemia resulting from disorders of synthesis in cases of severe liver parenchyma damage, increased intravascular consumption or increased loss.
AbcixiRel is the first monoclonal antibody from Reliance Life Sciences (RLS) and the first Indian abciximab biosimilar.
AbcixiRel is the FAB fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor sites on activated human platelets and inhibits platelet aggregation via fibrinogen binding. Abciximab also binds to the vitronectin (avß3) receptor found on platelets, vessel wall endothelial cells and smooth muscle cells.
AbcixiRel is indicated as an adjunct to percutaneous coronary intervention (PCI) for prevention of cardiac ischaemic complications in patients undergoing PCI and in patients with unstable angina unresponsive to conventional medical therapy when PCI is planned within 24 hours.
Abciximab has significant advantages compared to other molecules of same class like Eptifibatide and Tirofiban. Besides inhibition of platelet aggregation, abciximab has multiple benefits like anti-inflammatory effects and prevention of PCI related vessel wall hyperplasia and restenosis, and curbing of bleeding complications etc.
AbcixiRel is a clear, colourless, sterile, non-pyrogenic solution for intravenous use. AbcixiRel (2mg/ml) is available in 5 ml vial containing abciximab 10 mg.
AdaliRel (Adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). AdaliRel has human heavy and light chain variable regions and human IgG1k constant regions. AdaliRel has a molecular weight of approximately 148 kDa.
Adalimumab has been approved for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s disease, Ulcerative Colitis, Moderate to Chronic plaque psoriasis, Juvenile idiopathic arthritis, Hidradenitis Suppurativa and Uveitis.
AdaliRel is supplied as a sterile, 20 mg and 40 mg liquid in single-use prefilled syringes for subcutaneous administration.
BevaciRel (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody that binds and inhibits biological activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementary determining regions of a murine antibody.
Molecular weight of BevaciRel is 149 kDa. Bevacizumab has been approved for Metastatic Colorectal Cancer (mCRC), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Glioblastoma, Metastatic Renal Cell Carcinoma (mRCC), Persistent, Recurrent, or Metastatic Carcinoma of the Cervix, and Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
BevaciRel is available as a clear, sterile solution of 100 mg/4ml single use vial and 400 mg/16ml single use vial for infusion
ChorioRel is recombinant chorionic gonadotrophin hormone (r-hCG). It belongs to a class of hormones called gonadotrophins, which are involved in normal control of reproduction. ChorioRel is indicated in women undergoing assisted reproductive techniques (ART) such as in-vitro fertilization (IVF) to bring about ovulation trigger (release of eggs).
ChorioRel is a glycoprotein containing two sub-units. The alpha subunit is of 92 amino acids and beta subunit is of 145 amino acids. It is manufactured by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells. Recombinant hCG, since it is a pure protein product, containing only hCG and no other contaminants or free proteins, subcutaneous administration is advocated. Thus there is high patient compliance associated with the product. Also the amino acid sequence of ChorioRel is identical to that of native hCG.
ChorioRel is available as ready to use pre-filled syringes in two strengths, 250 mcg in 0.5 ml fill volume and 100 mcg in 0.2 ml fill volume.
ImmunoRel® is a solvent detergent treated, chromatographically purified immunoglobulin G(IgG) derived from pooled human plasma.
The approved indications include Primary Immunodeficiency (PID), Kawasaki disease, Idiopathic Thrombocytopenic Purpura, B-cell Chronic lymphocytic leukaemia, Paediatric HIV 1 infection and Hemopoietic stem cell transplantation in elderly.
The clinical experience has also shown efficacy in GB syndrome, Multifocal Motor Neuropathy, CIDP, Lambert Eaton Myasthenic syndrome, Myasthenia Gravis, Neonatal Sepsis, Polymyositis, Dermatomyositis and few others.
The normal immunoglobulin is meant for intravenous use. ImmunoRel® is available in 5% concentrations in 10 ml, 20 ml, 50 ml and 100 ml pack sizes.
Darbepoetin alfa is a glycoprotein analog of erythropoietin (EPO). Darbepoetin alfa is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. Darbepoetin alfa differs from human recombinant erythropoietin (rHuEPO) in containing of 5 N-linked oligosaccharide chains (instead of 3 chains in the ruHuEPO). However, due to the additional carbohydrate chains, darbepoetin alfa has an approximately 3-fold longer terminal half-life and longer in-vivo biological activity than rHuEPO. It stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.
DarbeRel is indicated for the treatment of anemia in adult and pediatric patients with chronic kidney disease (CKD), including patients receiving dialysis and patients not receiving dialysis, and for the treatment of anemia in adult patients with nonmyeloid malignancies when anemia is due to concomitantly administered chemotherapy.
DarbeRel is available as pre-filled syringes in the strengths of 25 mcg, 40 mcg, 60 mcg.
EtanerRel (Etanercept) is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the 55- kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). The mechanism of action of EtanerRel is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive. EtanerRel may also modulate biologic responses controlled by additional downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or regulated by TNF.
EtanerRel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). EtanerRel can be initiated in combination with methotrexate (MTX) or used alone. EtanerRel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients of two years and older. EtanerRel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis and improving physical function in patients with psoriatic arthritis (PsA). EtanerRel can be used with or without methotrexate. EtanerRel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). EtanerRel is indicated for the treatment of patients four years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
EtanerRel is available as multi-dose vial of lyophilized etanercept containing 25 mg of Etanercept, to be reconstituted with 1ml of bacteriostatic water for injection (reconstituted etanercept concentrate contains approximately 25 mg/mL of etanercept). EtanerRel is administered by subcutaneous (SC) injection.
FostiRel is recombinant follitropin beta stimulating hormone (r-FSH). FSH is a fertility hormone that is responsible for folliculogenesis and ovulation in females. It also indicated for spermatogenesis in males.
Amongst females with infertility, ovulatory problems like anovulation are responsible for around 25% of cases, while in case of males, azoospermia or oligzoospermia are most prominent contributing reasons.
Recombinant FSH, since it is a pure protein product, containing only FSH and no contaminants, subcutaneous administration is advocated. In this case, the pharmacokinetics does not seem to be affected. Subcutaneous administration, in fact, improves the patient compliance.
FostiRel is available as multi dose vials in strengths of 300 IU, 900 IU and 1200 IU. Multiple tests prove the product to be exactly similar to the innovator, in terms of product identity and purity.
InflixiRel is a recombinant chimeric human-murine IgG1? monoclonal antibody, which binds to both soluble and trans membrane forms of the human tumor necrosis factor (TNF)a and inhibits the functional activity of TNFa.
InflixiRel consists of two heavy and two light chains covalently linked by disulfide bonds and has molecular weight of 149 kDa. Infimab™ has been approved for treatment of rheumatoid arthritis (RA), Crohn’s disease (CD), ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis and ulcerative colitis (UC).
InflixiRel is available in 100 mg single use vials as sterile white lyophilized powder for intravenous infusion, to be reconstituted with 10 ml of sterile water for injection.
MIRel (Reteplase) is a single chain deletion mutant of alteplase that is expressed in Escherichia coli and, therefore, is expressed as an unglycosylated protein (355 amino acids) with a total molecular weight of 39 kDa.
The molecule consists of cringle 2 and the protease domain of the alteplase molecule. Because of the deletion of the fibronectin finger region, the binding of reteplase to fibrin is significantly reduced in comparison with that of alteplase. Although kringle 2 (known to stimulate protease in the presence of fibrin) is part of the reteplase molecule, reteplase is stimulated in the presence of fibrin to a lower extent than alteplase, suggesting that the fibronectin finger is involved in the stimulation of the protease as well.
Reteplase, in comparison with alteplase, is characterised by reduced fibrin selectivity. In the abscence of fibrin, reteplase and alteplase do not differ with respect to their activity as plasminogen activators, nor do they differ with respect to their inhibition by the plasminogen activator inhibitor type 1 (PAI-1).
The elimination of reteplase from the circulating plasma predominantly occurs in the liver. Because of the deletion of the fibronectin finger region, the epidermal growth factor domain and kringle 1, as well as the carbohydrate side chains, the hepatic elimination of the molecule is reduced. Consequently, plasma half life is increased to 14-18 minutes (versus 3-4 minutes with alteplase).
This allows reteplase to be administered as boli (versus as an initial bolus followed by an infusion, as with alteplase). The best results have been obtained with a double bolus of 10 U each 30 minutes apart in the case of an acute myocardial infarction.
Reteplase was superior to alteplase (administered over three hours) with respect to patency of the infarct related coronary artery. With reteplase patency was reached earlier and more frequently than with alteplase.
Each kit of MIRel contains two vials of 10 units of Reteplase each, sterile water for injection, two syringes and four needles
OmaliRel™ (Omalizumab) is a humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It binds to the FcεR1 epitope of human IgE, preventing human IgE from binding to its receptor on mast cells and basophils; thus inhibiting the histamine release response normally triggered by exposure to allergens.
OmaliRel™ is indicated for adult patients with moderate to severe persistent asthma, who have a positive skin test, or, in vitro reactivity to a perennial aeroallergen, or, whose symptoms are inadequately controlled with inhaled corticosteroids. It is indicated for the treatment of adult patients with chronic idiopathic urticaria who remain symptomatic despite H1 antihistamine treatment.
OmaliRel™ is available in a kit form with a vial containing the lyophilized product in 150 mg strength. Each kit also contains a sterile WFI vial, syringes, needles and alcohol swabs.
Pegfilgrastim is used to reduce the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils (a type of blood cell needed to fight infection). Pegfilgrastim is also used to increase the chance of survival in people who have been exposed to harmful amounts of radiation, which can cause severe and life-threatening damage to bone marrow. Pegfilgrastim is in a class of medications called colony stimulating factors. It works by helping the body make more neutrophils.
Long-acting G-CSFs (Pegfilgrastim) have been modified to increase molecular size and thus evade clearance by the kidneys. Instead of renal clearance, long-acting G-CSFs are cleared from the body predominantly by circulating neutrophils. As a result, serum levels of long-acting G-CSFs remain high during neutropenia but decrease as neutrophil levels return to normal.
Pegfilgrastim is produced by covalently binding a 20-kd polyethylene glycol (PEG) molecule to the N terminus of filgrastim. Pegfilgrastim stimulates the production and maturation of neutrophil precursors and enhances the functions of mature neutrophils in the same manner as filgrastim.
In most studies, patients treated with pegfilgrastim had a lower risk of Febrile Neutropenia (FN) than those who received short-acting G-CSFs. Pegfilgrastim has pharmacological advantages over daily G-CSFs that makes it easily administrable, thus reducing the chance of incorrect delivery. For patients at higher risk of failure with daily G-CSF prophylaxis (e.g. risk of noncompliance, difficulties on performing regular hemograms, high risk of developing febrile neutropenia), pegfilgrastim might be the most appropriate option.
RanizuRel™ (Ranibizumab) is a recombinant humanized IgG1K isotype monoclonal antibody fragment that selectively binds to inhibit biological activity of human vascular endothelial growth factor A (VEGF-A). It is produced in an E.Coli expression system and has a molecular weight of 48 kilodaltons.
RanizuRel™ is indicated in Neovascular (Wet) Age-Related Macular Degeneration (AMD) and administered by intravitreal injection. It is recommended to administer RanizuRel once a month (approximately 28 days). The intravitreal injection procedure should be carried out under controlled aseptic conditions.
RanizuRel™ is sterile, preservative-free, clear colourless to pale yellow solution available in 0.5 mg dose single-use vial.
Interferons are a family of naturally occurring proteins and glycoproteins that are produced by eukaryotic cells in response to viral infection and other biological inducers. Interferon beta, a member of interferon family, is produced by various cell types including fibroblasts and macrophages.
Recombinant interferon beta-1a is a glycosylated protein with a single N-linked glycosylation site, similar to the natural interferon beta-1a.
ReliBeta (recombinant Interferon beta-1a) is a 166 amino acid glycoprotein with a molecular weight of approximately 22 kDa. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of ReliBeta® is identical to that of natural human interferon beta.
ReliBeta is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (CIS) and relapsing-remitting multiple sclerosis (RRMS) in adults.
ReliBeta is a sterile, preservative-free, clear colourless liquid for intramuscular injection.
ReliBeta is available as a ready for use pre-filled glass syringe with 0.5 ml fill volume. Each 0.5 ml in a pre-filled glass syringe contains 30 µg of interferon-beta-1a in sodium acetate aqueous buffer containing L-arginine hydrochloride and polysorbate 20.
ReliFeron belongs to the class of interferons (IFNs) which are natural proteins produced by the cells of the immune system in response to foreign agents such as viruses, bacteria, parasites and tumor cells.
Interferons are produced in body primarily from leukocyte, fibroblast and immune cell and the important ones are α, β, and γ. Interferons assist the immune response by activating natural killer cells and macrophages, promoting antigen presentation to lymphocytes and thus inducing the resistance of host cells against foreign agents. Interferons also have direct anti-viral effects.
Recombinant IFN-a is now approved worldwide in over 40 countries for the treatment of more than 14 malignancies and viral diseases, including adjuvant therapy in metastatic melanoma, condyloma acuminata, Kaposi’s sarcoma and most importantly hepatitis B and C. Interferon-a has been shown to be effective in suppressing viral replication and in inducing remission of liver disease caused by chronic hepatitis B and hepatitis C virus infection.
ReliFeron is a purified sterile human recombinant interferon product classified as an alpha interferon. It has 165 amino acids, with a molecular weight of 19 kDa. ReliFeron is obtained by recombinant technology using Escherichia coli with an interferon alpha 2b gene from human leukocytes. It is used in the form of parenteral injection.
Each vial of ReliFeron contains 3 or 5 million IU recombinant human interferon alpha 2b in 0.5 mL of aqueous buffer.
ReliGrast is human recombinant Granulocyte Colony Stimulating Factor (G-CSF), which is a specific growth factor known to stimulate production of neutrophils, a type of white blood cells in the body that are essential for fighting infections. It is active during the normal course of hematopoiesis and the hematopoietic stem cells get differentiated into white blood cells in the presence of G-CSF.
G-CSF is a protein having 175 amino acids, and has no glycosylation. E.coli is used for commercial manufacturing of recombinant G-CSF as a biosimilar. ReliGrast can be therapeutically used for reversing neutropenic conditions due to various reasons. It can be used in chemotherapy induced neutropenia, AIDS-associated neutropenia, congenital, cyclic idiopathic neutropenia. In the clinical trials conducted, ReliGrast has demonstrated efficacy in reducing the duration of Neutropenia (compared to 9 days) and recovery after ANC Nadir. The reduction in the incidence of Febrile Neutropenia, Grade 4 Neutropenia and Infection is also significant.
ReliGrast is available in the strength of 300 mcg/0.5 ml, as a pre-filled syringe.
Erythropoietin (EPO) belongs to the class of Erythropoiesis Stimulating Agents, i.e it work as a growth hormone and stimulates production of red blood cells from the hematopoietic stem cells in the bone marrow. It is solely produced by the kidney cells, and thus, any functional damage to the kidneys can result in EPO deficiency and reduction in production of RBC pool that eventually leads to anemia.
ReliPoietin is erythropoietin alpha, conventionally used to reverse anemic condition that is arising because of body’s inability to produce required amount of erythropoietin, and thus, reduced pool of red blood cells. It is used as a support therapy in the treatment of Acute, chronic and end-stage renal failure; in cancer-induced and chemotherapy-related anemia; in patients undergoing major surgeries; and in AIDS patients on zidovudine treatment. The aim of therapy is to reduce the number of dialysis required by the renal failure patients, better tolerance of chemotherapy and reduced number of blood transfusions in case of cancer patients; and overall improved quality of life in these patients.
ReliPoietin, is a glycoprotein containing 165 amino acids. The molecular weight is 30 kD, with 40% glycosylation. The upstream processing including the cell lines (Chinese Hamster Ovary) used and the downstream processing yields erythropoietin that is exactly similar to the innovator’s product. Even the isoform distribution, which is one of the determinants of efficacy, is same as that of the innovator’s product and the biological reference protein.
ReliPoietin is available as pre-filled syringes in the strengths of 2000, 3000, 4000, 6000, 10,000 and 40,000 IU
RituxiRel (Rituximab) is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. At present, Rituximab is the most important mAb of clinical value in patients with B-cell lymphoid malignancies.
Rituximab has an approximate molecular weight of 145 kDa. Rituximab has a binding affinity for the CD20 antigen of approximately 8.0 nM. CD20 is expressed relatively on selected B cells from the pre-B-cell stage until post germinal cells differentiate to become plasma cells.
RituxiRel is approved for Non-Hodgkin’s Lymphoma (NHL), Rheumatoid Arthritis (RA), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) and Pemphigus Vulgaris (PV).
RituxiRel comes in 100 mg/10 mL in single-use vial and 500 mg/50 mL in single use vial.
SomatoRel (r-hGH), a recombinant human growth hormone (r-hGH) is a similar biologic to innovator somatropin. It has been produced by recombinant DNA technology using genetically engineered Picha pastoris cells which have been transformed with the HGH gene and cultured in fermentors. The recombinant HGH protein has an amino acid sequence that is identical to the natural sequence predicted from the human DNA sequence analysis.
The overall molecular weight of recombinant HGH is approximately 22 kDa.
SomatoRel (r-hGH) is indicated for the treatment of pediatric patients, with growth failure due to inadequate secretion of endogenous growth hormone (GH), with short stature associated with Noonan syndrome, Turner syndrome and with short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4 years.
The dosage and administration schedule of SomatoRel (r-hGH) should be individualized based on the growth response of each patient.
SomatoRel (r-hGH) can be stored for 24 months at 2° to 8° C from the date of manufacturing.
SomatoRel (r-hGH) is supplied as a sterile solution for subcutaneous injection at a strength of 5 mg in a vial and is meant to be delivered in multiple doses.
TenecteRel (Tenecteplase) is the latest third generation tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese Hamster Ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle -1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain.
Tenecteplase has advantages of single bolus administration, least time for administration, highest resistance to plasminogen activator inhibitor (PAI) and high fibrin specificity.
TenecteRel (Tenecteplase) is indicated for use in the reduction of mortality associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms.
TenecteRel (Tenecteplase) is the only fibrinolytic, which is recommended as half dose in patients > 75 years of age.
TenecteRel (Tenecteplase) is for intravenous administration only. The dose is weight-based and should not exceed 50 mg. A single bolus dose should be administered over five seconds based on patient weight.
TenecteRel (Tenecteplase) is available as 30, 40 and 50 mg kits. Each kit of TenecteRel® contains one Tenecteplase lyophilized vial (30/40/50 mg), sterile water for injection, one sterile disposable syringe, two needles and three alcohol swabs.
TrastuRel (Trastuzumab) is a humanized IgG1 kappa recombinant monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2), a transmembrane receptor protein coded by a proto-oncogene. TrastuRel contains human framework regions and the complementary determining regions of a murine antibody.
Molecular weight of TrastuRel is around 149kDa. TrastuRel is currently approved for breast cancer and metastatic gastric cancer.
TrastuRel is available as sterile 150mg and 440mg lyophilized powder in vials for intravenous administration.
DenosuRel™ (Denosumab) is a human monoclonal antibody (IgG2) that binds to receptor activator of nuclear factor-kB ligand (RANKL), a protein that is essential for formation, function, and survival of osteoclast. It disrupts the RANKL/RANK interaction, prevents fusion and activation of osteoclasts, thus reducing bone resorption. It is produced in genetically engineered mammalian Chinese hamster ovarian (CHO) cells and has a molecular weight of 147 kDa.
DenosuRel™ is indicated in prevention of skeletal-related events in patients with multiple myeloma, or, in bone metastases from solid tumors, or, in hypercalcemia of malignancy refractory to bisphosphonate therapy. Bone metastasis and resorption of bone are common sequelae in these patients because of overexpression of protein RANKL.
DenosuRel™ (denosumab) is available in a single-use vial, as 120mg dose in 1.7ml solution.
DenOsteoRel™ (Denosumab) is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand). Denosumab has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.
DenOsteoRel™ (Denosumab) is a sterile, preservative-free, clear, colorless to pale yellow solution available as a 1 mL single-use vial and a single-dose prefilled syringe that contains 60 mg of denosumab (60 mg/mL solution).
DenOsteoRel™ (Denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
GolimuRel (Golimumab) is a fully human IgG1κ monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human TNF-α, which prevents the binding of TNF-α to its receptors. The protein has an approximate molecular weight of 150 KDa and exhibits multiple glycoforms. GolimuRel (Golimumab) is produced by a recombinant cell line process.
GolimuRel (Golimumab) is indicated currently in combination with methotrexate for the treatment of adult patients with moderately to severely active Rheumatoid Arthritis. It is also indicated for patients with active Ankylosing Spondylitis.
UstekiRel (Ustekinumab) is a fully human IgG1κ monoclonal antibody that binds with high affinity and specificity to a shared subunit of interleukins IL-12 and IL-23, thereby inhibiting their activity in the inflammation process. UstekiRel (Ustekinumab) is produced by a recombinant cell line process. The protein has an approximate molecular weight of 148.6 KDa and exhibits multiple glycoforms.
UstekiRel (Ustekinumab) is currently indicated for the treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
AzatiRel ™ (Azacitidine for Injection) contains Azacitidine IP, which is a pyrimidine Nucleoside analog of cytidine. Azacitidine is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow.
Azacitidine is indicated for treatment of patients with the following French-American- British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
The finished product is supplied in a sterile form for reconstitution as a suspension for subcutaneous injection or reconstitution as a solution with further dilution for intravenous infusion. AzatiRel™ (Azacitidine for injection) is available in 100 mg single-use vials packaged in cartons of 1 vial. Each vial of AzatiRel™ contains 100 mg of Azacitidine IP and 100 mg mannitol as a sterile lyophilized powder.
BortiRel (Bortezomib) for Injection is an antineoplastic agent available for intravenous injection (IV) or subcutaneous use (SC). Bortezomib is a modified dipeptidyl boronic acid. Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins.
BortiRel (bortezomib) for Injection is a proteasome inhibitor indicated for Multiple Myeloma part of combination therapy for the treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell transplantation and for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for stem cell transplantation. BortiRel® is also indicated for Mantle Cell Lymphoma for the treatment of patients with mantle cell lymphoma who have relapsed or were refractory to at least one prior therapy.
It is available in strengths: 1 mg, 2 mg and 3.5 mg.
ErlotiRel (Erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).
Erlotinib has been approved by FDA for maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. It is also approved for the treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen and is a first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. Erlotinib is also approved by EMEA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.
ErlotiRel (Erlotinib) tablets for oral administration are available in dosage strengths equivalent to 25 mg, 100 mg and 150 mg Erlotinib.
Imatinib mesylate is an orally administered, synthetic tyrosine kinase inhibitor (three known targets are ABL, c-kit, PDGF receptor). It is rapidly absorbed , and is highly bioavailable. Most of imatinib is eliminated as metabolites, only 25% of it is eliminated unchanged. The half-lives of imatinib and its main metabolite are 18 and 40 hours respectively.
It is used in the treatment of chronic myeloid leukaemia (CML) and GIST. It is also approved as a single agent for the treatment of dermatofibrosarcoma protuberans (DFSP), myelodysplastic / myeloproliferative diseases (MDS/MPD), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL), and relapsed/refractory Philadelphia chromosome positive acute lymphocytic leukemia (Ph+ ALL).
ImatiRel is available as 100 and 400 mg tablets.
Isabis is a dermal filler gel of Sodium hyaluronate generated by Streptococcus species of bacteria. It is produced biotechnologically by natural fermentation. Isabis is a viscous gel supplied in a prefilled glass syringe together with needles for injection.
Isabis is formulated as a clear gel and uses a dual mechanism of action to correct moderate to severe wrinkles and folds. Upon being injected beneath the skin’s surface, Isabis gel integrates into dermal tissue then attracts and binds to water molecules to help maintain volume. Isabis is gradually degraded by the body’s own mechanism and disappears without any residue. Results can be seen immediately following Isabis treatment and for up to six months. Some patients may achieve results that last longer than six months, depending upon injection site.
Isabis is available in three formulations based on particle size- Isabis Fine, Isabis Contour and Isabis Restore. Isabis FINE is indicated for facial tissue augmentation. It is recommended as dermal filler for wrinkles and lip augmentation. Isabis CONTOUR is indicated for facial tissue augmentation. It is recommended to be used for shaping the contours of the face, correction of folds and lip enhancement. Isabis RESTORE is indicated for facial tissue augmentation. It is recommended to be used for shaping pronounced contours of the face and for volume augmentation.
Isabis FINE is supplied in one ml long glass pre-filled syringe with 1 ml fill volume. Isabis CONTOUR is supplied in one ml glass prefilled syringe with 1 ml fill volume. Isabis RESTORE is supplied in two ml glass pre-filled syringe with 2 ml fill volume.
Leuprolide acetate is a synthetic nonapeptide analogue of naturally occurring gonadotropin-releasing hormone (GnRH or LH-RH). The analogue possesses greater potency than the natural hormone. It is available in a vial which, when mixed with diluents, become a suspension intended as a monthly intramuscular/ subcutaneous injection.
LeuproRel™ DEPOT developed as a depot preparation of Leuprolide acetate using micro-encapsulated formulation demonstrated continuous release of the drug for 4 weeks and the effective suppression of testosterone after a subcutaneous injection monthly.
LeuproRel™ is indicated in endometriosis and uterine leiomyomata (Fibroids). LeuproRel™ Depot is to be administered subcutaneously/ intramuscularly, varying the injection site periodically, depending on the indication, under the supervision of a physician.
Each composite pack of LeuproRel™DEPOT 3.75 mg contains: One vial of Lyophilized powder of Leuprolide acetate, one ampoule of diluent for reconstitution (2 ml), one sterile syringe, two needles and one alcohol swab. To be reconstituted with diluent.
Capecitabine is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered systemic prodrug which is converted to 5-fluorouracil.
Capecitabine is indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. It is also indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred and in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
ReliCitabine is available as 150 mg and 500 mg tablets. These two strengths help provide best possible dosing and also help in better dose titration for the patients.
Lenalidomide, a thalidomide analogue, is an immunomodulatory agent with antiangiogenic and antineoplastic properties. Lenalidomide is an off-white to pale-yellow solid powder. Lenalidomide is more soluble in organic solvents and low pH solutions. Lenalidomide is available has hard capsules in the strengths of 5 mg, 10 mg, 15 mg and 25 mg capsules for oral administration. Each capsule contains lenalidomide as the active ingredient.
Lenalidomide was developed to reduce the dose limiting side effects of thalidomide such as sedation, constipation, thromboembolism and neuropathy. The mechanism of action of this class of agents remains to be fully characterized, but it inhibits TNFáproduction, stimulates T andNK cells, reduces serum levels of vascular endothelial growth factor (VEGF), promotes G1 cellcycle arrest and apoptosis of malignant cells.
Lenalidomide is indicated for the treatment of patients with Multiple myeloma (MM), in combination with dexamethasone, in patients who have received at least one prior therapy. It is also indicated for use in transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities and for the treatment of Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. Lenalidomide is also indicated in Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL).
Lenalidomide as available has hard capsules in the strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration. Each capsule contains lenalidomide as the active ingredient.
Pemetrexed disodium heptahydrate is chemotherapeutic agent and it falls in the class of anti-metabolites. It is supplied as a sterile lyophilized powder for intravenous infusion available in single-dose vials. Each 100-mg or 500-mg vial of ReliTrexed® contains pemetrexed disodium equivalent to 100 mg pemetrexed or 500 mg.
Pemetrexed is indicated in combination with cisplatin therapy, for the initial treatment of patients, with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). It is also indicated in combination with pembrolizumab and platinum chemotherapy, for metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. It is used as a single agent for the treatment of patients, with locally advanced or metastatic nonsquamous NSCLC, after prior chemotherapy and in combination with cisplatin. It is indicated for patients with malignant mesothelioma, when the disease is unresectable, or, for those, who are otherwise not candidates for curative surgery.
ReliTrexed® is available in 100 and 500 mg vials.
Sodium Hyaluronate is the sodium salt of hyaluronic acid (HA). HA is a carbohydrate, more specifically a mucopolysaccharide, occurring naturally in all living organisms. It can be several thousands of sugards (carbohydrates) long. When not bound to other molecules, it binds to water giving it a stiff viscous quality similar to ‘Jello’.
HA plays a vital role in development of cartilage, maintenance of the synovial fluid and regeneration of tendons. High concentrations of HA have been found in extracellular matrix (ECM) of all adult joint tissues, including the synovial fluid and outer layer of cartilage. In part because of its viscoelastic nature and ability to form highly hydrated matrices, HA acts in joint as a lubricant and shock absorber.
Viscosupplementation is a novel, safe and effective form of local treatment for osteoarthritis. Viscosupplementation in HA products helps to improve physiological environment in an osteoarthritic joint by supplementing shock absorption and lubrication properties of osteoarthritic synovial fluid. The rationale for using viscosupplementation is to restore the protective viscoelasticity of synovial hyaluronan, decrease pain, and improve mobility. The immediate benefit of viscosupplementation is relief of pain. Long-term benefits are believed to include return of joint mobility by restoration of transsynovial flow and, ultimately, metabolic and rheologic homeostasis of joint.
SynoLife™/SynoLife™ One is a formulation for viscosupplementation prepared from non-animal origin hyaluronic acid. It is a sterile, non-pyrogenic, elastoviscous fluid containing sodium hyaluronate stabilized with cross-linked derivative of sodium hyaluronate.
SynoLife™/SynoLife™ One contain sodium hyaluronate stabilized with cross-linked derivative of sodium hyaluronate (20 mg per ml) in buffered physiological sodium chloride solution (pH 7.2± 0.3). It contains high concentration of sodium hyaluronate which is pre-treated for improving the purity and stabilized with cross-linked sodium hyaluronate for improved stability and better rheology. The product is terminally sterilized by steam sterilization thus giving guaranteed sterility.
SynoLife™/SynoLife™ One is indicated for treatment of pain associated with osteoarthritis (OA) of the knee in patients who have not had an adequate response to non-pharmacologic conservative measures (e.g. weight loss, exercise, etc.) and simple analgesics (e.g. paracetamol and other nonsteroidal anti-inflammatory drugs).
SynoLife™ is available as a 2 ml (40 mg) injection containing 2% Sodium Hyaluronate in 2.25 ml glass syringe. It is also available in a pack of three injections.
SynoLife™ One is available as a 6 ml (120 mg) injection containing 2% Sodium Hyaluronate in 10 ml glass syringe.
Temozolomide is a prodrug, orally administered alkylating agent of the imidazotetrazine class, rapidly and completely absorbed, at physiological pH, spontaneously hydrolyzed into the active metabolite.
Temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Temozolomide capsules are also indicated for the treatment of adult patients with refractory anaplastic astrocytoma, i.e. patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.
TemoRel is available as capsules of 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which includes two unique strengths – 140 and 180 mg.
Reliance Life Sciences is the first company in India to launch Temozolomide in 140 mg and 180 mg strengths. With TemoRel 140 mg and 180 mg doctors now have options to provide best possible dosing to their patients including the ones with very high or very low body surface areas. These two strengths also provide convenience to patient and reduce number of capsules to be taken per dose.
Terlipressin (also known as triglycyl lysine vasopressin) is a synthetic analogue of the neuropeptide hormone vasopressin and a pro drug for lysine vasopressin. Terlipressin has affinity for vasopressin receptors (V receptors). V receptors are divided into three specific subtypes (V1, V2 and V3), the distribution and density of which account for the potential pharmacological effects including vasoconstrictive effects.
TerliRel™ is administered by bolus intravenous injection and is indicated for Bleeding oesophageal varices (BOV) and Type 1 hepatorenal syndrome (HRS).
TerliRel™ is available as 10 ml glass vial and contains 0.1mg per ml of Terlipressin.
SorafiRel™ (Sorafenib) is a multikinase inhibitor. It works by slowing down the rate of growth of cancer cells and cutting off the blood supply that helps cancer cells grow.
Sorafenib is indicated for the treatment of patients, with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). Sorafenib is also indicated for the treatment of patients, with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.
SorafiRel™ (Sorafenib) tablets for oral administration are available in dosage strengths equivalent to 200 mg.
DecitaRel™ (Decitabine) exerts its antineoplastic effects after phosphorylation, causing hypomethylation of DNA and cellular differentiation, or apoptosis. Decitabine-induced hypomethylation in neoplastic cells, may restore normal function to genes, critical for the control of cellular differentiation and proliferation.
Decitabine is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated de novo and secondary MDS of all French-American-British subtypes and International Prognostic Scoring System groups of intermediate-1, intermediate-2 and high-risk.
DecitaRel™ (decitabine) is available in a vial as 50mg lyophilized powder for reconstitution and intravenous administration.
| DRUG NAME | STRENGTH | PACKING |
|---|---|---|
| 3% SODIUM HYALURONATE + 4% CHONDROITIN SULPHATE | 1 X 1ML PFS | |
| ABIRATERONE ACETATE 250MG TABLET | 250MG | 1 X 30 TABS |
| ABIRATERONE ACETATE 500MG TABLET | 500MG | 1 X 60 TABS |
| ABIRATERONE ACETATE TABLETS IP | 500 MG | 1 X 60 TABS |
| ACEBROPHYLLINE 100 MG AND N-ACETYLCYSTEINE 600 MG TABLETS | 10 X 10 TABS | |
| ACETYLCYSTEINE EFFERVESCENT TABLETS | 600 MG | 1 X10 TABS |
| AMITRIPTYLINE HCL | 10MG | 10 X 10 TABS |
| AMPHOTERICIN B POWDER FOR INJECTION 50 MG LYOPHILISED | 50MG | 1 VIAL |
| BETHANECHOL CHLORIDE 25MG TABLET | 25MG | 5 X 10 TABS |
| BETHANECHOL CHLORIDE 50MG TABLET | 50MG | 5 X 10 TABS |
| BETHANECHOL CHLORIDE SUSTAINEDRELEASE TABLET | 75 MG | 5 X 10 TABS |
| BICALUTAMIDE TABLET 50MG TABLET | 50MG | 10 X 10 TABS |
| BORTEZOMIB FOR INJECTION | 2MG | 1 VIAL |
| BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJ USP | 20MG/4ML | 5 X 4ML AMP |
| CALCIUM CARBONATE (CORAL FORM) 500 MG & VITAMIN D3 500 IU | 1 X 10 TABS | |
| CAP. ESTRAMUSTINE PHOSPHATE BP | 140MG | 3 X 10 CAPS |
| CAP. HYDROXYUREA BP | 500MG | 10 X 10 CAPS |
| CAP. IMATINIB | 100MG | 12 X 10 CAPS |
| CAP. PHENOXYBENZAMINE BP | 10MG | 5 X 10 CAPS |
| CAP.PENICILLAMINE | 250MG | 5 X 10 CAPS |
| CAP.TEMOZOLOMIDE | 20 MG | 1 X 5 CAPS |
| CAP.TEMOZOLOMIDE | 100 MG | 1 X 5 CAPS |
| CAP.TEMOZOLOMIDE | 250 MG | 1 X 5 CAPS |
| CARBETOCIN INJECTION 100MCG/ML | 100MCG/ML | 5 X 1ML VIAL |
| CASPOFUNGIN ACETATE FOR INJECTION | 50 MG | 1 X 50MG VIAL |
| CEFTAZIDIME & AVIBACTAM POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION | 2.5GM | 1 VIAL |
| CETRORELIX ACETATE INJ | 0.25MG / 0.5 ML | 1 PFS |
| CETRORELIX ACETATE FOR INJECTION(LYOPHILIZED) | 0.25MG | 1 VIAL |
| CHLORAMPHENICOL 4MG + POLYMYXIN B 5000 IU + DEXAMETHASONE 1MG | DROP | 1 X 5 ML BOTTLE |
| CHLORAMPHENICOL 4MG + POLYMYXIN B 5000 IU + DEXAMETHASONE 1MG | OINTMENT | 1 X 5 GM TUBE |
| CISATRACURIUM BESYLATE INJ - USP | 10MG/5ML (2MG/ML) | 1 VIAL |
| CISATRACURIUM BESYLATE INJ - USP | 20MG/10ML (2MG/ML) | 1 VIAL |
| CLARITHROMYCIN FOR INJECTION 500 MG | 500 MG | 1 VIAL |
| COLISTIMETHATE SODIUM 1MIU | 1MIU | 1MIU VIAL |
| COLISTIMETHATE SODIUM 2MIU | 2MIU | 2MIU VIAL |
| COLISTIMETHATE SODIUM 3MIU | 3MIU | 3MIU VIAL |
| COLISTIMETHATE SODIUM 4.5MIU | 4.5MIU | 1 VIAL |
| DASATINIB 100MG | 100MG | 1 X 30TABS |
| DASATINIB 50MG | 50MG | 1 X 60 TABS |
| DASATINIB 70MG | 70MG | 1 X 60TABS |
| DEGARELIX FOR INJ 120MG (LYOPHILIZED) | 120MG | 1 VIAL |
| DEGARELIX FOR INJ 80MG (LYOPHILIZED) | 80MG | 1 VIAL |
| DEHYDROEPIANDROSTERONE SUSTAINED RELEASE TAB 75 MG | 75MG | 1 X 7 TABS |
| DEXAMETHASONE TABLET IP 4MG | 4MG | 10 X 10 TABS |
| DEXAMETHASONE TABLET IP 8MG | 8MG | 10 X 10 TABS |
| DIENOGEST TABLETS 2 MG | 2MG | 1X10 TABS |
| DOCETAXEL INJECTION IP | 120 MG | 1 VIAL |
| DOCETAXEL INJECTION IP | 20 MG | 1 VIAL |
| DOCETAXEL INJECTION IP | 80 MG | 1 VIAL |
| DOXORUBICIN HCL (LYOPHILISED) I.P | 10MG | 1 X 5ML VIAL |
| DOXORUBICIN HCL (LYOPHILISED) I.P | 50MG | 1 X 25ML VIAL |
| DOXORUBICIN HYDROCHLORIDE INJECTION IP | 50MG | 1 VIAL |
| DOXORUBICIN HYDROCHLORIDE INJECTION IP | 10MG | 1 VIAL |
| DOXORUBICIN HYDROCHLORIDE LIPOSOMAL INJECTION(PEGYLATED LIPOSOMAL) | 2MG /ML | 1 X 10ML VIAL |
| DYDROGESTERONE TABLETS IP | 10 MG | 1 X 10 TABS |
| EACH VIAL CONAIN SOMATOSTATIN 3MG - LYPHOLIZED | 3MG | 1 VIAL |
| EDETATE CALCIUM DISODIUM INJ. | 200MG | 1 X 2 AMP |
| ENALAPRIL MALEATE TABS I.P | 2.5MG | 10 X 15 TABS |
| ENTECAVIR TABLETS IP | 0.5 MG | 1 X 30 TABS |
| ENZALUTAMIDE 160MG | 160MG | 1 X 7 TABS |
| ENZALUTAMIDE 40MG CAPSULE | 40MG | 1 X 28 CAPS |
| ENZALUTAMIDE 40MG CAPSULE | 40MG | 2 X 28 CAPS |
| ERLOTINIB TAB 150MG | 150MG | 1X10 TABS |
| ERTAPENEM FOR INJECTION | 1 GM | 1 X 1GM VIAL |
| EXEMESTANE TABLETS IP | 25MG | 3 X 10TABS |
| FAROPENEM SODIUM EXTENDED RELEASE TABLETS | 300MG | 1 X 6 TABS |
| FERROUS ASCORBATE (SR), L-METHYL FOLATE, MECOBALAMIN, BIOTIN, CHOLECALCIFEROL, PYRIDOXAL-5-PHOSPHATE, ZINC & 8 MINERALS | 2 X 15TABS | |
| FERROUS FUMARATE, VITAMIN C & FOLIC ACID SACHET | 20 X 2 GM | 20 X 2GM SACHET |
| FOSFOMYCIN TROMETHAMINE | 3GM | 10 X 1 X 8G SACHET |
| FULVESTRANT INJ - 250MG/5ML | 250MG/5ML | 1 X 5ML PFS |
| FUROSEMIDE ORAL SOLUTION USP | 300MG/30ML | 30ML BOTTLE |
| GLUTATHIONE (LYOPHILIZED) | 600MG | 1 VIAL |
| GLYCOPYRROLATE + NEOSTIGMINE METHYLSULPHATE INJECTION | 5ML | 5 X 5 ML |
| GLYSERINE 10% W/V & MANNITOL 10 % W/V | 100 ML | 100 ML BOTTLE |
| HEPARIN SODIUM GEL | 200 IU | 1 X 20GM TUBE |
| HUMAN NORMAL IMMUNOGLUBULIN 5% IP | 0.05 | 1 BOTTLE |
| HUMAN ALBIMIN 20 % IP | 0.2 | 100ML BOTTLE |
| HYALURONIDASE INJECTION 15000 IU | 15000 IU | 1 X 10 VIAL |
| INJ FOSFOMYCIN SODIUM INJ | 4GM | 1 VIAL |
| INJ CEFTRIAXONE AND TAZOBACTUM 1GM +125 MG | 1.125 GM | 1 VIAL |
| INJ HYDROCORTISONE SODIUM SUCCINATE | 100MG | 1 X 100MG VIAL |
| INJ ULINASTATIN 1000IU | 1000 IU | 1 VIAL |
| INJ. ACYCLOVIR SODIUM USP | 250 MG | 1 VIAL |
| INJ. ACYCLOVIR SODIUM USP | 500MG | 1 VIAL |
| INJ. AMINOCAPROIC ACID I.P | 5 GM/20ML | 1 X 20ML VIAL |
| INJ. AMIODARONE HCL BP | 150MG/3ML | 5 X 3 ML AMP |
| INJ. ATRACURIUM BESYLATE USP | 25MG/2.5ML | 5 X 2.5 AMP |
| INJ. ATRACURIUM BESYLATE USP | 100MG/10ML | 1 VIAL |
| INJ. ATRACURIUM BESYLATE USP | 50 MG/5ML | 5 X 5ML AMP |
| INJ. CARDIOPLEGIA SOLUTION IP | 20ML | 5 X 20ML AMP |
| INJ. CEFOPERAZONE SODIUM USP | 1 GM | 1 VIAL |
| INJ. CEFTAZIDIME USP | 1 GM | 1 VIAL |
| INJ. DIGOXIN I.P | 0.5 MG/2ML | 10 X 2ML AMP |
| INJ. DOBUTAMINE HCL U.S.P(AMP) | 250 MG/5ML | 2 X 5ML AMP |
| INJ. DOPAMINE HCL USP | 200 MG/5ML | 5 X 5 X 5ML AMP |
| INJ. FLUORESCEIN SODIUM | 600 MG | 5 X 3 ML AMP |
| INJ. ISOPRENALINE HCL I.P | 2 MG/1ML | 5 X 1ML AMP |
| INJ. NITROGLYCERIN USP | 25 MG/5ML | 5 X 5 X 5ML AMP |
| INJ. NITROGLYCERIN USP | 50 MG/10ML | 5 X 10ML AMP |
| INJ. NORADRENALINE BITARTRATE IP | 4 MG/2ML | 20 X 2ML AMP |
| INJ. PHENYLEPHRINE HCL I.P | 10 MG/1ML | 1 X 1 ML AMP |
| INJ. PHYTOMENADIONE BP | 1 MG/0.5ML | 1 X 10 AMP |
| INJ. PHYTOMENADIONE BP | 1 MG/0.5ML | 1 X 25 AMP |
| INJ. PHYTOMENADIONE BP | 10 MG/1ML | 10 X 1ML VIAL |
| INJ. PHYTOMENADIONE BP | 10 MG/1ML | 25 X 1ML VIAL |
| INJ. POLIDOCANOL | 0.03 | 2 X 2 ML AMP |
| INJ. PROTAMINE SULPHATE | 50 MG/5ML | 5 X 5X 5ML AMP |
| INJ. ALPROSTADIL (PROSTAGLANDIN E1) USP | 500MCG/1ML | 1 X 1ML AMP |
| INJ. CEFTRIAXONE & SULBACTAM | 1.5 GM | 1 VIAL |
| INJ. CEFTRIAXONE SODIUM IP | 1GM | 1 VIAL |
| INJ. POLYMYXIN B. SULPHATE BP | 5,00,000 U | 1 VIAL |
| INJ. POLYMYXIN B. SULPHATE BP | 7,50,000 U | 1 VIAL |
| INJ. SODIUM NITROPRUSSIDE USP | 50 MG | 1 X 50 MG VIAL |
| INJ. SODIUM TETRADECYL SULPHATE BP | 0.03 | 2 X 2ML AMP |
| INJ. VERAPAMIL HCL I.P. | 5MG/2ML | 10 X 2ML AMP |
| INJ. 2-PYRIDINE ALDOXIME METHIODIDE 25MG,METHLY PARABEN IP 1.8MG,PROPYL PARABEN IP 0.2MG, WATER FOR INJ IP Q.S. | 500MG/20ML | 2 X 20ML AMP |
| INJ. ANIDULAFUNGIN 100MG | 100MG | 1 VIAL |
| INJ. BIVALIRUDI | 250MG | 1 VIAL |
| INJ. BUPIVACAINE IP | 0.005 | 1 X 20ML VIAL |
| INJ. CALCIUM FOLINATE | 50 MG | 1 X 5ML |
| INJ. CALCIUM FOLINATE | 15 MG | 10 X 2ML |
| INJ. CARBOPROST TROMETHAMINE | 250MCG | 2 X 5 X 1ML AMP |
| INJ. CEREBROPROTEIN HYDROLYSATE | 60MG | 1 VIAL |
| INJ. CHORIONIC GONADOTROPHIN IP ( HIGHLY PURIFIED) | 5000 I.U | 1 VIAL |
| INJ. CHORIONIC GONADOTROPHIN IP ( HIGHLY PURIFIED) | 10000 I.U | 1 VIAL |
| INJ. CHORIONIC GONADOTROPHIN IP ( HIGHLY PURIFIED) | 2000 I.U | 1 VIAL |
| INJ. COLISTEMETHATE SODIUM | 1MIU | 1 VIAL |
| INJ. COLISTEMETHATE SODIUM | 2MIU | 1 VIAL |
| INJ. COLISTEMETHATE SODIUM | 3MIU | 1 VIAL |
| INJ. COLISTEMETHATE SODIUM | 4.5MIU | 1 VIAL |
| INJ. DEXMEDETOMIDINE HYDROCHLORIDE | 50MCG/0.5ML | 1 X 0.5ML AMP |
| INJ. DEXMEDETOMIDINE HYDROCHLORIDE | 100MCG/1ML | 1 X 1ML AMP |
| INJ. DEXMEDETOMIDINE HYDROCHLORIDE | 200MCG/2ML | 1 X 2ML AMP |
| INJ. DOBUTAMINE POWDER FOR INJECTION USP | 250 MG | 1 VIAL |
| INJ. DOXYCYCLINE INJ | 100MG | 1 VIAL |
| INJ. EPIRUBICIN HCL | 10MG | 1 VIAL |
| INJ. EPIRUBICIN HCL | 50MG | 1 VIAL |
| INJ. ESMOLOL HYDROCHLORIDE | 100MG/10ML | 1 X 10ML VIAL |
| INJ. FILGRASTIM 300 MCG | 300 MCG | 1 PFS |
| INJ. GEMCITABINE HCL USP | 200MG | 1 VIAL |
| INJ. GEMCITABINE HCL USP | 1GM | 1 VIAL |
| INJ. GLYCOPYRROLATE USP | 0.2MG/1ML | 10 X 1ML AMP |
| INJ. HEPARIN SODIUM IP | 10IU/ML | 1 X 10ML VIAL |
| INJ. HEPARIN SODIUM IP | 25,000 I.U./5ML | 1 X 5ML VIAL |
| INJ. HEPARIN SODIUM IP | 5,000I.U/5ML | 1 X 5ML VIAL |
| INJ. IMIPENEM & CILASTATIN | 500MG+500MG | 1 VIAL |
| INJ. IMIPENEM & CILASTATIN | 500MG+500MG | 1 VIAL |
| INJ. LABETALOL HCL BP | 100MG | 1 X 20ML AMP |
| INJ. LABETALOL HCL BP | 20MG | 2 X 4ML AMP |
| INJ. LEVOCARNITINE | 1GM | 5 X 5ML AMP |
| INJ. LIGNOCAINE HYDROCHLORIDE IP | 0.02 | 10 X 30 ML VIAL |
| INJ. MEROPENEM | 1GM | 1 VIAL |
| INJ. MEROPENEM | 1000MG | 1 VIAL |
| INJ. MEROPENEM | 500MG | 1 VIAL |
| INJ. MEROPENEM & SULBACTUM | 1.5GM | 1 VIAL |
| INJ. MEROPENEM IP | 1GM | 1 VIAL |
| INJ. MEROPENEM IP & SULBACTAN | 1.5GM | 1 VIAL |
| INJ. MEROPENEM USP | 1GM | 1 X 1GM VIAL |
| INJ. MEROPENEM USP | 500MG | 1 X 500MG VIAL |
| INJ. MICAFUNGIN SODIUM | 50MG | 1 VIAL |
| INJ. MILRINONE LACTATE | 10MG/10ML | 1 X 10ML AMP |
| INJ. NALOXONE HCL USP | 0.4MG/ML | 5 X 1ML AMP |
| INJ. NETILMICIN SULPHATE USP | 300MG/3ML | 1 X 3ML AMP |
| INJ. OXALIPLATIN | 50MG | 1 VIAL |
| INJ. OXALIPLATIN | 100MG | 1 VIAL |
| INJ. PHENOXYBENZAMINE BP | 50MG/ML | 1 X 1ML AMP |
| INJ. POLYMIXIN-B SULPHATE | 5,00,000 IU | 1 VIAL |
| INJ. TERLIPRESSIN | 1MG/10ML | 1X10ML AMP |
| INJ. TRANEXAMIC ACID BP | 500MG/5ML | 5 X 5 X 5ML AMP |
| INJ. VASOPRESSIN IP | 20 I.U/1ML | 5 X 1ML AMP |
| INJ. ZOLEDRONIC ACID (LYOPHILIZED) | 4MG/5ML | 1 VIAL |
| INJ.ADENOSINE | 6MG/2ML | 1 X 2ML AMP |
| INJ.AMOXICILLIN+CLAVULANATE POTASSIUM | 1GM+200MG | 1 VIAL |
| INJ.ARTESUNATE BP | 60MG | 1 VIAL |
| INJ.BUSERELIN ACETATE | 0.5 MG/0.5 ML | 1 AMP |
| INJ.BUSERELIN ACETATE | 7 MG/7 ML | 1 VIAL |
| INJ.CEFOPERAZONE SODIUM USP +SULBACTAM SOD. | 1GM+0.5GM | 1 VIAL |
| INJ.DIMERCAPROL IP | 100MG | 2 X 2ML AMP |
| INJ.DOCETAXEL | 120MG | 1 VIAL |
| INJ.DOCETAXEL | 20MG | 1 VIAL |
| INJ.DOCETAXEL | 80MG | 1 VIAL |
| INJ.OCTREOTIDE | 50MCG | 1 X 1ML AMP |
| INJ.OCTREOTIDE | 100MCG | 1 X 1ML AMP |
| INJ.PIPERACILLIN SOD AND TAZOBACTAM SOD | 2GM+250MG | 1 VIAL |
| INJ.PIPERACILLIN SOD AND TAZOBACTAM SOD | 4GM+500MG | 1 VIAL |
| INJ.PIPERACILLIN SOD AND TAZOBACTAM SOD | 4GM+500MG | 1 VIAL |
| INJ.SODIUM BICARBONATE IP | 8.4%W/V | 5 X 25ML AMP |
| INJ.TIGECYCLINE | 50 MG. | 1 VIAL |
| INJ.VANCOMYCIN HYDROCHLORIDE USP | 500MG | 1 VIAL |
| INJ.VANCOMYCIN HYDROCHLORIDE USP | 1 GM | 1 VIAL |
| IRON SUCROSE INJECTION | 100 MG/5 ML | 5 X 5 ML AMP |
| IRON SUCROSE INJECTION | 100 MG/5 ML | 1 X 5 ML AMP |
| ISOFLURANE IP | 30ML | 1 BOTTLE |
| ISOFLURANE IP | 100ML | 1 BOTTLE |
| ISOFLURANE IP | 250ML | 1 BOTTLE |
| L-ASAPARAGINASE 10000 IU/VIAL | 10000 I.U | 1 VIAL |
| L-CARNITINE,L-TARTRATE,COENZYME Q10,ZINC SULPHATE MONOHYDRATE,LYCOPENE,CUCUMIS MELO EXTRACT TABLETS | 1 X 10TABS | |
| L-ORNITHINE L-ASPARTATE GRANULES | 10GM/SACHET | 1 X 10 SACHET |
| L-ORNITHINE-L- ASPARTATE INFUSION CONCENTRATE | 5GM/10ML | 1 X 10ML AMP |
| L-ORNITHINE-L- ASPARTATE SACHET | 5GM/SACHET | 1 X 10 SACHET |
| LACTIC ACID WITH SEA BUCKTHORN OIL,TEA TREE OIL & CRANBERRY | 100ML | 1 X 100ML BOTTLE |
| LACTITOL MONOHYDRATE AND ISPAGHULA HUSK GRANULES | 90GM | 1HDPE BOTTLE OF 90GM |
| LACTITOL MONOHYDRATE AND ISPAGHULA HUSK GRANULES | 180GM | 1HDPE BOTTLE OF 180 GM |
| LACTITOL MONOHYDRATE AND ISPAGHULA HUSK GRANULES | 90GM | 1HDPE BOTTLE OF 90GM |
| LACTITOL MONOHYDRATE AND ISPAGHULA HUSK GRANULES | 180GM | 1HDPE BOTTLE OF 180GM |
| LACTOBACILLUS RHAMNOSUS GG (ATCC 53103) DROPS | DROP | 1 X 8 ML BOTTLE |
| LACTOBACILLUS RHAMNOSUS GG (ATCC 53103) DROPS | DROP | 1 X 3.5 ML BOTTLE |
| LAPATANIB | 250MG | 1 X 30 TABS |
| LAPATANIB | 250MG | 1 X 150 TABS |
| LEUPROLIDE ACETATE FOR INJECTION | 11.25MG | 1 VIAL |
| LEUPROLIDE ACETATE FOR INJECTION | 22.5MG | 1 VIAL |
| LEUPROLIDE ACETATE FOR INJECTION (DEPOT) 11.25 MG | 11.25 MG | 1 VIAL |
| LEUPROLIDE ACETATE FOR INJECTION (LYOPHILIZED) | 3.75 MG | 1 VIAL |
| LEUPROLIDE ACETATE INJECTION | 1 MG /0.5 ML | 1 X 1 ML AMP |
| LEUPROLIDE ACETATE INJECTION | 4 MG/4 ML | 1 VIAL |
| LEUPROLIDE INJECTION | 11.25 INJ | 1 VIAL |
| LEUPROLIDE INJECTION | 22.5 INJ | 1 VIAL |
| LEUPROLIDE INJECTION | 3.75 INJ | 1 VIAL |
| LIPOSOMAL AMPHOTERICIN B INJECTION | 50MG | 1 VIAL |
| MENOTROPHIN FOR INJECTION | 225 I.U | 1 PFS |
| MENOTROPHIN FOR INJECTION BP ( HIGHLY PURIFIED) | 75 I.U | 1 VIAL |
| MENOTROPHIN FOR INJECTION BP ( HIGHLY PURIFIED) | 150 I.U | 1 VIAL |
| MENOTROPIN INJ 150 I U /0.5ML | 150IU | 1 PFS |
| MENOTROPIN INJECTION | 600 I.U | 1 ML |
| MENOTROPIN INJECTION | 1200 I.U | 2 ML |
| METHYLCOBALAMIN 750MCG,ADENOSYLCOBALAMIN 750MCG,VITAMINS B1 ,B2,B6 &FOLIC ACID 1.5MG CAPSULES | 750MCG/750MCG/5MG/5MG/3MG/1.5MG | 1 X 15 CAPS |
| METHYLENE BLUE INJ USP | 10MG/ML | 5 X 10ML AMP |
| METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJ USP | 1 GM | 1 VIAL |
| METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJ USP | 500 MG | 1 VIAL |
| METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJ USP | 125 MG | 1 VIAL |
| METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJ USP | 40 MG | 1 VIAL |
| MICRONISED PURIFIED FLAVONOID FRACTION OF RUTACEAE | 1000MG | 2 X 10 TABS |
| MINOCYCLINE FOR INJECTION USP | 100 MG | 1 VIAL |
| MONTELUKAST 10 MG & ACEBROPHYLLINE 200 MG (SUSTAINED RELEASE) TABLETS | 1 X 10 TABS | |
| MOXIFLOXACIN 0.5% & DEXAMETHASONE PHOSPHATE 0.1% | DROP | 1 X 5ML BOTTLE |
| MYOINOSITOL 550 MG, D-CHIRO-INOSITOL 13.8 MG, VITAMIN D3 200 IU, CHROMIUM PICOLINATE 100 MCG | 1 X 10 TABS | |
| N- ACETYLCYSTEINE INJECTION 20% BP | 400MG | 20 X 2ML AMP |
| N- ACETYLCYSTEINE INJECTION 20% BP | 200MG | 5 X 1ML AMP |
| N- ACETYLCYSTEINE INJECTION 20% BP | 200MG | 5 X 5 X 1ML AMP |
| N- ACETYLCYSTEINE INJECTION 20% BP | 1GM | 5 X 5 X 5 ML AMP |
| N-BUTYLCYANOACRYLATE | 0.5 ML | 5 X 0.5 ML AMP |
| N-BUTYLCYANOACRYLATE | 1 ML | 5 X 1 ML AMP |
| N-BUTYLCYANOACRYLATE 1ML,SCLEROTHERAPY NEEDLE-21G-1 UNIT,CLEANSING FLUID-1BOTTLE & SYRINGES-2UNITS. | 1ML KIT | 1X1ML KIT |
| NATURAL MICRONIZED PROGESTERONE 200 MG SUSTAINED RELEASE | 1 X 10 TABS | |
| NATURAL MICRONIZED PROGESTERONE 300 MG SUSTAINED RELEASE | 300MG | 1X10 TABS |
| NEPAFENAC OPHTHALMIC SUSPENSION | DROP | 1 X 5 ML BOTTLE |
| NIFEDIPINE (0.3% W/W), LIDOCAINE (1.5% W/W) | 30GM | 1 X 30GM TUBE |
| NITROFURANTOIN 100MG SR TABLET | 100MG | 10 X 14 TABS |
| OCTREOTIDE LONG ACTING RELEASE INJECTION | 20MG | 1 VIAL |
| OCTREOTIDE LONG ACTING RELEASE INJECTION | 30 MG | 1 VIAL |
| PACLITAXEL (PROTEIN BOUND PARTICLES) FOR INJECTABLE SUSPENSION | 100MG | 1 VIAL |
| PACLITAXEL 100MG | 100MG | 1 VIAL |
| PACLITAXEL 260MG | 260 MG | 1 VIAL |
| PACLITAXEL 30MG | 30 MG | 1 VIAL |
| PACLITAXEL INJECTION IP | 260 MG | 1 VIAL |
| PACLITAXEL INJECTION IP | 100 MG | 1 VIAL |
| PACLITAXEL INJECTION IP | 30 MG | 1 VIAL |
| PALBOCICLIB CAPSULES 100 MG | 100 MG | 1 X 21 CAPS |
| PALBOCICLIB CAPSULES 125 MG | 125 MG | 1 X 21 CAPS |
| PALBOCICLIB CAPSULES 75 MG | 75 MG | 1 X 21 CAPS |
| PARACETAMOL INFUSION (PLASTIC) | 10MG | 100ML BOTTLE |
| PARACETAMOL INFUSION (GLASS) | 10MG/ML | 1 X 100ML BOTTLE |
| PEGASPARGASE INJECTION | 3750 IU / 5 ML | 1 X 5ML VIAL |
| PEMETREXED FOR INJECTION | 100 MG | 1 VIAL |
| PEMETREXED FOR INJECTION | 500MG | 1 VIAL |
| PLERIXAFOR INJECTION | 20MG | 1 VIAL |
| POTASSIUM CITRATE + MAGNESIUM CITRATE + VIT. B6 ORAL SYRUP | 200ML | 1 X 200ML BOTTLE |
| POTASSIUM CITRATE + MAGNESIUM CITRATE + VIT. B6 ORAL SYRUP | 450ML | 1 X 450ML BOTTLE |
| POTASSIUM PHOSPHATES INJECTION USP | 15ML | 1 AMP |
| PREFILLED SYRINGE ENOXAPARIN SODIUM | 40MG | 1 X 0.4ML PFS |
| PREFILLED SYRINGE ENOXAPARIN SODIUM | 60MG | 1X0.6ML PFS |
| PREFILLED SYRINGE ENOXAPARIN SODIUM | 40MG | 1 PFS |
| PREFILLED SYRINGE VASOPRESSIN IP | 40 I.U/1ML | 1 X 1ML PFS |
| PROGESTERONE CAPSULES | 100 MG | 3 X 10 CAPS |
| PROGESTERONE CAPSULES | 200 MG | 3 X 10 CAPS |
| PROGESTERONE CAPSULES | 400 MG | 3 X 10 CAPS |
| PROGESTERONE INJECTION BP | 100 MG | 5 X 1 ML AMP |
| PROGESTERONE INJECTION BP | 200 MG | 5 X 2 ML AMP |
| PROPOFOL INJECTION IP | 20ML | 1 VIAL |
| PROPOFOL INJECTION IP | 10ML | 1 VIAL |
| PROPOFOL INJECTION IP | 50ML | 1 VIAL |
| PROPRANOLOL PROLONGED-RELEASE CAPSULES IP | 20MG | 10 X 10CAPS |
| PRUCALOPRIDE TABLET 1MG. | 1MG | 10 X 10 TABS |
| PRUCALOPRIDE TABLET 2MG. | 2MG | 10 X 10 TABS |
| RAMOSETRON HYDROCHLORIDE TABLETS | 5 MCG | 5 X 15 TABS |
| RIBAVIRIN CAPS USP 200MG | 200MG | 1 X 40 CAPS |
| RIFAXIMIN TABLETS | 400MG | 10 X 10TABS |
| RIFAXIMIN TABLETS | 550MG | 10 X 10 TABS |
| ROCURONIUM BROMIDE INJ | 50MG/5ML(10 MG/ML) | 1 VIAL |
| ROCURONIUM BROMIDE INJ | 100MG/10ML (10 MG/ML) | 1 VIAL |
| ROPIVACAINE HYDROCHLORIDE INJECTION USP | 0.002 | 1 X 20ML AMP |
| ROPIVACAINE HYDROCHLORIDE INJECTION USP | 0.0075 | 1 X 20ML AMP |
| SEVOFLURANE USP | 50ML | 1 BOTTLE |
| SEVOFLURANE USP | 250ML | 1 BOTTLE |
| SILODOSIN 8MG + DUTASTERIDE 0.5MG TABLET | 8MG+0.5MG | 10 X 15 TABS |
| SILODOSIN 8MG TABLET | 8MG | 10 X 15 TABS |
| SNAKE VENOM ANTISERUM IP | 10ML | 5 X 10ML VIAL |
| SOFOSBUVIR 400MG + VELPATASVIR 100MG | 1 X 28 TABS | |
| SORAFENIB 200 MG | 200MG | 1 X 30TABS |
| SORAFENIB 200 MG | 200MG | 1 X 120TABS |
| SPIRONOLACTONE TABLETS IP | 50MG | 10 X 15 TABS |
| STERILE LIGNOCAINE HYDROCLHORIDE GEL IP | 0.02 | 1 X 30GM TUBE |
| STERILE POTASSIUM CHLORIDE CONCENTRATE INJ. BP | 15% W/V | 5 X 10 ML AMP |
| STREPTOKINASE FOR INJECTION I.P.(LYOPHILIZED) | 15LAC I.U | 1 VIAL |
| SUCRALFATE 7%+METRONIDAZOLE 1%+LIGNOCAINE 4% | 20GM | 1 X 20GM TUBE |
| SUNITINIB MALATE CAPSULES 12.5MG | 12.5MG | 1 X 7 CAPS |
| SUNITINIB MALATE CAPSULES 25MG | 25MG | 1 X 7 CAPS |
| SUNITINIB MALATE CAPSULES 50MG | 50MG | 1 X 7 CAPS |
| SYP. DIGOXIN PEDIATRIC I.P | 3MG/60ML | 1 X 60ML BOTTLE |
| TAB ANASTRAZOLE 1 MG | 1 MG | 10 X 5 TABS |
| TAB LABETALOL 100 MG | 5 X 10TABS | |
| TAB. PHYTOMENADIONE BP | 10MG | 2 X 10 TABS |
| TAB. AMIODARONE BP | 200MG | 10 X 10 TABS |
| TAB. AMIODARONE BP | 100MG | 10 X 10 TABS |
| TAB. ANASTRAZOLE | 1MG | 1 X 10 TABS |
| TAB. BACLOFEN BP | 10 MG | 20 X 10 TABS |
| TAB. CALCIUM ACETATE | 667MG | 10 X 10 TABS |
| TAB. CALCIUM FOLINATE I.P | 15 MG | 2 X 10 TABS |
| TAB. DIGOXIN I.P | 0.25 MG | 20 X 10TABS |
| TAB. FLUDROCORTISONE ACETATE IP | 100MCG | 20 X 10 TABS |
| TAB. FLUTAMIDE USP | 250 MG | 3 X10 TABS |
| TAB. GEFITINIB | 250MG | 3 X 10 TABS |
| TAB. HYDROCORTISONE USP | 10MG | 20 X 10 TABS |
| TAB. HYDROCORTISONE USP | 5MG | 20 X 10 TABS |
| TAB. HYDROCORTISONE USP | 20MG | 5 X 10 TABS |
| TAB. IMATINIB | 400MG | 3 X 10 TABS |
| TAB. LETROZOLE USP | 2.5MG | 3 X 10 TABS |
| TAB. LETROZOLE USP | 2.5MG | 3 X 5 TABS |
| TAB. LETROZOLE USP | 2.5MG | 3 X 5 TABS |
| TAB. MEGESTROL ACETATE BP | 40 MG | 3 X 10 TABS |
| TAB. MEGESTROL ACETATE BP | 160 MG | 3 X 10 TABS |
| TAB. PYRIDOSTIGMINE BROMIDE BP | 60 MG | 5 X 10 TABS |
| TAB. SOTALOL HCL BP | 40MG | 5 X 10 TABS |
| TAB. TAMOXIFEN CITRATE I.P. | 10 MG | 10 X 10 TABS |
| TAB. TAMOXIFEN CITRATE I.P. | 20 MG | 10 X 10 TABS |
| TAB.ABIRATERONE ACETATE | 250 MG | 1 X 120 TABS |
| TAB.ABIRATERONE ACETATE | 250 MG | 1 X 30 TABS |
| TAB.ACETYLCYSTEINE | 600MG | 2 X 10 TABS |
| TAB.BICALUTAMIDE | 50MG | 3 X 10 TABS |
| TAB.CAPECITABINE | 500MG | 3 X 10 TABS |
| TAB.LABETALOL BP | 100MG | 5 X 10 TABS |
| TADALAFIL 5MG TABLET | 5 MG | 10 X 10 TABS |
| TAMSULOSIN 0.4MG + DEFLAZACORT 30MG TABLETS | 4MG+30MG | 1 X 10 TABS |
| TAMSULOSIN 0.4MG + DUTASTERIDE 0.5MG TABLET | 0.4MG | 1 X 15 TABS |
| TAMSULOSIN 0.4MG CAPSULE | 0.4MCG | 1 X 15 CAPS |
| TEICOPLANIN FOR INJECTION (LYOPHILIZED) | 400MG | 1 VIAL |
| TENOFOVIR ALAFENAMIDE TABLETS IP | 25 MG | 1 X 30 TABS |
| TENOFOVIR DISOPROXIL FUMARATE TABLETS IP | 300 MG | 1 X 30 TABS |
| TICARCILLIN & CLAVULANIC ACID FOR INJECTION IP | 3.1GM | 1 VIAL |
| ULIPRISTAL ACETATE 5MG TABLETS | 5MG | 1 X 10 TABS |
| UROFOLLITROPHIN FOR INJECTION BP (HIGHLY PURIFIED) | 75 I.U | 1 VIAL |
| UROFOLLITROPHIN FOR INJECTION BP (HIGHLY PURIFIED) | 150 I.U | 1 VIAL |
| URSODEOXYCHOLIC ACID SUSTAINED RELEASE TABLETS | 600MG | 10 X 10 TABS |
| URSODEOXYCHOLIC ACID TABLET IP | 150MG | 10 X 10 TABS |
| URSODEOXYCHOLIC ACID TABLET IP | 300MG | 10 X 10 TABS |
| VECURONIUM BROMIDE FOR INJECTION (LYOPHILIZED) | 10MG | 1 VIAL |
| VECURONIUM BROMIDE FOR INJECTION (LYOPHILIZED) | 4MG | 1 X 5 VIAL |
| VITAMIN D3 ORAL SOLUTION | 5ML | 4 X 5ML BOTTLE |